Details of the Target
General Information of Target
Target ID | LDTP03164 | |||||
---|---|---|---|---|---|---|
Target Name | UDP-glucuronosyltransferase 1A1 (UGT1A1) | |||||
Gene Name | UGT1A1 | |||||
Gene ID | 54658 | |||||
Synonyms |
GNT1; UGT1; UDP-glucuronosyltransferase 1A1; UGT1A1; EC 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDPGT 1-1; UGT1*1; UGT1-01; UGT1.1; UDP-glucuronosyltransferase 1A isoform 1
|
|||||
3D Structure | ||||||
Sequence |
MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQLQQRGHEIVVL
APDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFENDSFLQRVIKTYKKIKKDS AMLLSGCSHLLHNKELMASLAESSFDVMLTDPFLPCSPIVAQYLSLPTVFFLHALPCSLE FEATQCPNPFSYVPRPLSSHSDHMTFLQRVKNMLIAFSQNFLCDVVYSPYATLASEFLQR EVTVQDLLSSASVWLFRSDFVKDYPRPIMPNMVFVGGINCLHQNPLSQEFEAYINASGEH GIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDL LGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTS EDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHD LTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH |
|||||
Target Type |
Clinical trial
|
|||||
Target Bioclass |
Enzyme
|
|||||
Family |
UDP-glycosyltransferase family
|
|||||
Subcellular location |
Endoplasmic reticulum membrane
|
|||||
Function |
[Isoform 1]: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile. Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds. Catalyzes the glucuronidation of endogenous estrogen hormones such as estradiol, estrone and estriol. Involved in the glucuronidation of bilirubin, a degradation product occurring in the normal catabolic pathway that breaks down heme in vertebrates. Also catalyzes the glucuronidation the isoflavones genistein, daidzein, glycitein, formononetin, biochanin A and prunetin, which are phytoestrogens with anticancer and cardiovascular properties. Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist losartan, a drug which can inhibit the effect of angiotensin II. Involved in the biotransformation of 7-ethyl-10-hydroxycamptothecin (SN-38), the pharmacologically active metabolite of the anticancer drug irinotecan.; [Isoform 2]: Lacks UGT glucuronidation activity but acts as a negative regulator of isoform 1.
|
|||||
TTD ID | ||||||
Uniprot ID | ||||||
DrugMap ID | ||||||
Ensemble ID | ||||||
HGNC ID | ||||||
ChEMBL ID |
Target Site Mutations in Different Cell Lines
Probe(s) Labeling This Target
ABPP Probe
Probe name | Structure | Binding Site(Ratio) | Interaction ID | Ref | |
---|---|---|---|---|---|
DBIA Probe Info |
![]() |
C127(1.35) | LDD2379 | [1] | |
Acrolein Probe Info |
![]() |
N.A. | LDD0221 | [2] |
Competitor(s) Related to This Target
The Interaction Atlas With This Target
The Drug(s) Related To This Target
Approved
Phase 2
Drug Name | Drug Type | External ID | |||
---|---|---|---|---|---|
At-342 | Gene therapy | D84EGX |
Investigative
Drug Name | Drug Type | External ID | |||
---|---|---|---|---|---|
Alvocidib | Small molecular drug | DB03496 | |||
Muraglitazar | Small molecular drug | DB06510 | |||
Curcumin Sulfate | . | DB14635 | |||
Lenacapavir | . | DB15673 | |||
Propacetamol | . | DB09288 |
References